Every 424B that Tharimmune, Inc. (THAR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow THAR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full THAR filings page.
Canton Strategic Holdings, Inc. is registering an at-the-market offering to sell up to $300,000,000 of its common stock under an amended Sales Agreement with Clear Street LLC and Virtu Americas LLC, permitting sales from time to time through or to the Sales Agents.
The program amends an earlier ATM arrangement, follows prior issuances including a January registered offering and a November PIPE, and permits negotiated or Rule 415(a)(4) at-the-market sales with commissions up to 3.0% of gross proceeds; timing and amounts sold are subject to the Sales Agreement terms.
Tharimmune, Inc. is conducting a primary offering of 1,800,000 shares of common stock and Pre-Funded Warrants to purchase up to 17,000,000 shares of common stock at $2.92 per share (or $2.9199 per Pre-Funded Warrant), for total gross proceeds of $54,894,300 and estimated net proceeds of about $52.7 million after fees.
The Pre-Funded Warrants are immediately exercisable at $0.0001 per share, do not expire, and are subject to beneficial ownership caps generally starting at 4.99%. Tharimmune plans to use the funds mainly to expand and develop its Canton-centric digital asset treasury strategy and for general corporate purposes. Assuming full exercise of the Pre-Funded Warrants, common shares outstanding would rise from 37,729,847 to 56,529,847, and new investors face estimated immediate dilution of $0.66 per share.
Tharimmune, Inc. has filed a prospectus covering the resale by existing investors of up to 176,934,358 shares of its common stock. These shares consist of 25,315,642 PIPE Shares, 151,456,115 shares issuable upon exercise of Pre-Funded Warrants, and 162,601 RSU Shares issued in connection with a November 2025 PIPE financing.
The company is not selling shares itself under this prospectus and will receive no proceeds from these resales. The underlying PIPE Transaction closed on November 6, 2025 and generated approximately $545 million in gross proceeds, with a limited portion earmarked for legacy biotech operations and the balance for fees and a Canton Coin–focused digital asset treasury strategy. Tharimmune plans to operate as a Super Validator on the Canton Network while continuing development of its immunology and inflammation therapeutic pipeline.
The company also established an ATM Program allowing sales of up to $64,910,161 of common stock through an at-the-market facility and implemented leadership changes to oversee the digital asset strategy.
Tharimmune, Inc. supplements its prospectus for a common stock sales program covering up to $64,910,161 of common stock under a Sales Agreement with Clear Street LLC and President Street Global, LLC.
The supplement discloses that President Street has given notice to terminate its role as a sales agent and that Tharimmune agreed to pay President Street an advisory fee of $1,000,000, in two $500,000 installments tied to the first sales notice and to aggregate sales of $50,000,000 of shares under the Sales Agreement. The company notes its common stock trades on the Nasdaq Capital Market under the symbol THAR, with a last reported sale price of $2.50 per share on December 4, 2025, and reminds investors to review the risk factors in its prospectus and recent SEC reports.
Tharimmune, Inc. filed a prospectus supplement to launch an at‑the‑market program to sell up to $64,910,161 of common stock through Clear Street LLC and President Street Global. The Sales Agents will use commercially reasonable efforts and may execute negotiated or Rule 415(a)(4) “at the market offerings,” with compensation of up to 3.0% of gross proceeds.
The company plans to use net proceeds primarily to acquire, hold and stake Canton Coin, operate validators on the Canton Network, and for working capital and general corporate purposes, including potential acquisitions or investments. Tharimmune’s common stock trades on Nasdaq as THAR; the last reported price was $3.99 on November 5, 2025. Shares outstanding were 34,933,919 as of November 6, 2025.
The filing follows a recently closed private placement that issued pre‑funded warrants and generated approximately $545 million in gross proceeds, with most of those proceeds allocated to a digital asset treasury strategy centered on Canton Coin.